BrainStorm Cell Therapeutics signals continued hope for NurOwn by securing patents, says GlobalData

Sample article from our R&D/Patents

February 1, 2024 (press release) –

BrainStorm Cell Therapeutics is still navigating a three-year regulatory journey for the NurOwn therapy that was initiated in February 2021, marked by the FDA’s initial discouragement of filing a Biologics License Application (BLA). However, the recent acquisition of three new patents for NurOwn and NurOwn-Exosomes remains a safeguard for NurOwn’s cell therapy, fostering hope for a strong market position upon potential approval in amyotrophic lateral sclerosis (ALS), says GlobalData, a leading data and analytics company.

GlobalData’s report “Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2029’’, reveals that developing disease-modifying treatments for this rare and aggressive disease has proven challenging. The high failure rate in ALS clinical trials is often attributed to the disease’s unclear etiology and complex pathophysiology, resulting in a persistent unmet need for effective treatments. NurOwn utilizes a process where a patient’s bone marrow-derived mesenchymal stem cells are treated in the lab to produce neurotrophic factors. These factors are then delivered through intrathecal injection into ALS patients to stimulate neuron regeneration and nerve-muscle interaction.

Despite failing to meet its primary endpoints in the Phase III trial, the results showed that treatment with NurOwn significantly elevated markers of neuroprotection and simultaneously decreased markers of neuroinflammation and neurodegeneration. Specifically, a 11% decrease in a biomarker known as neurofilament light (NfL) was observed.

Momna Ali, Healthcare Analyst at GlobalData, comments: “The impact of NurOwn on NfL is noteworthy, especially in light of the FDA’s recent approval of tofersen (Qalsody; Biogen). Similar to NurOwn, tofersen fell short of its primary endpoint. Tofersen, the first therapy for patients with SOD1 mutation-mediated ALS, gained approval based on reductions in the same biomarker.”

In December 2023, the European Patent Office has granted patent for NurOwn titled ‘Method of Qualifying Cells,’ outlining a process to determine if a cell population is a suitable therapeutic for ALS. Similarly, the Australian and Israeli Patent Offices have granted patents both titled ‘Cell-Type Specific Exosomes and Use Thereof,’ covering an isolated Exosomes population derived from MSC-NTF cells.

Ali concludes: “According to GlobalData’s Sales and Forecast Database, NurOwn is anticipated to generate global sales of $401 million in 2029 for ALS, both positioning Brainstorm Cell Therapeutics favorably for monetization and adding to the overall ALS treatment portfolio.”

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we're very happy to help.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

More from our R&D/Patents Coverage
See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order r&d/patents coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.